Welcome to QBiotics

An Australian naturally inspired life sciences company

Human Health
Animal Health
Investor Health

UPDATES


The first in-human Clinical Phase I study of intratumoural tigilanol tiglate has been published in The Lancet's EBioMedicine journal

December 2019

An efficacious dose was achieved and a Maximum Tolerated Dose (MTD) was not reached, indicating tigilanol tiglate tolerability in humans. Promising outcomes were attained in patients with a variety of solid tumour types, with a 27% treatment response, including 18% complete response (full tumour destruction). Following these positive results, a Phase I/II trial of tigilanol tiglate in patients with Head and Neck Squamous Cell Carcinoma (HNSCC) is underway, with the first patient successfully dosed.


QBiotics announces first patient dosed in its phase I/II clinical trial of tigilanol tiglate for head and neck cancer

December 2019

First patient successfully dosed in QBiotics' Phase I/II clinical trial of tigilanol tiglate in patients with Head and Neck Squamous Cell Carcinoma (HNSCC). Tigilanol tiglate is a novel, small molecule that is being tested as a single injection treatment for solid tumours. The Phase I/II clinical trial is a dose escalation study in HNSCC patients designed to determine optimal dosage, safety and tumour response. The QBC46-H03 trial is being run in Australia and India.


STELFONTA Progress with European Medicines Authority

November 2019

The European Medicines Authority, Committee for Medicinal Products for Veterinary Use (CVMP) adopted by majority a positive opinion for an initial marketing authorisation application for STELFONTA®, from QBiotics Group Limited.  This supports STELFONTA® (tigilanol tiglate) as an oncology veterinary product. Formal registration confirmation is expected early January.


Dr Susan Foden joined the Board of QBiotics

October 2019

Dr Susan Foden joined the Board of QBiotics as a non-executive director on 14 October 2019.


Scientific Presentations: Veterinary Cancer Society, Houston, USA

October 2019

The Veterinary Cancer Society (VCS) Conference is the largest scientific meeting for veterinary oncology professionals globally. This year over 670 veterinary oncologists and associated health professionals attended the conference in Houston, USA. QBiotics' anticancer product tigilanol tiglate was the subject of two abstracts selected by the VCS scientific committee for presentation during the conference.


Tigilanol tiglate canine mast cell tumour (MCT) pivotal field efficacy clinical trial results presented at prestigious international congresses

September 2019

Dr Chad Johannes DVM, Diplomate ACVIM (SAIM, Oncology) presented the tigilanol tiglate canine mast cell tumour (MCT) pivotal field efficacy clinical trial results at two recent prestigious international congresses


International Publication - Tigilanol Tiglate Canine Dose Characterisation Study

11 April 2019

The tigilanol tiglate canine dose characterisation study has been published as an original research article in the leading international journal, Frontiers in Veterinary Science.